Journal profile · CLINICAL NEUROLOGY-PSYCHIATRY
Neuropsychiatric Disease and Treatment
ISSN 1178-2021 · Dove Medical Press · NEW ZEALAND
Neuropsychiatric Disease and Treatment: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.22; JCR Q2 (journal website); fully open access; APC about USD 3,940; median 85 days to acceptance (107 articles, last 24 months); acceptance rate 12% (journal website); 218 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Neuropsychiatric Disease and Treatment is published by Dove Medical Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Schizophrenia research and treatment, Treatment of Major Depression and Tryptophan and brain disorders, together about 29.7% of its articles. Its main subfields are Psychiatry and Mental health. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Dr Roger M Pinder Neuropsychiatric Disease and Treatment is an international, peer reviewed, open access journal publishing on all aspects of neuropsychiatric and neurological disorders. The journal is characterized by the rapid reporting of new and emerging clinical or pre-clinical studies, pharmacology and therapeutic strategies to overcome a wide range of conditions as well as the diagnosis, prognosis, epidemiology and genetic associations of these diseases. All meta-analyses require a pre-submission check prior to submitting to Neuropsychiatric Disease and Treatment. Please complete the pre-submission check form here. Topics covered in this journal include: Biological basis and clinical treatment of Neuropsychiatric conditions such as Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorders, Anxiety and Depressive Disorders, Bipolar Disorders and Schizophrenia Biological basis and clinical treatment of Neurological conditions such as Dementia, Parkinson’s Disease, Epilepsy, Multiple Sclerosis, Migraines, and Neuropsychiatric Consequences of Strokes Research on the normal brain which gives insight into potential dysfunction, disease or the mechanisms of treatments The journal welcomes submitted papers covering original research, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports/series submitted to Neuropsychiatric Disease and Treatment will be diverted to the Neuropsychiatric Disease and Treatment section of the International Medical Case Reports Journal (Journal metric data for this journal can be accessed here). When considering submission of a paper utilizing publicly available data, authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors’ own data through replication in an original sample. Updated 13 July 2026
From the journal's Aims & Scope
Research area (LetPub): CLINICAL NEUROLOGY-PSYCHIATRY
Editor-in-chief Chen ClinicalPublisher website
Editorial board by country: 3 in mainland China (about 10%); most named United States 11, Italy 8, Japan 4, Mainland China 3, United Kingdom 2 (31 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Schizophrenia research and treatmentMedicine12.3%
- Treatment of Major DepressionMedicine9%
- Tryptophan and brain disordersNeuroscience8.3%
- Bipolar Disorder and TreatmentMedicine6.7%
- Attention Deficit Hyperactivity DisorderMedicine4.3%
- Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychology4.2%
- Dementia and Cognitive Impairment ResearchMedicine4.2%
- Parkinson's Disease Mechanisms and TreatmentsMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Psychiatry | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Clinical Neurology | Zone 3 |
| Minor | Psychiatry | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Psychiatry | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.22LetPub ·
- Impact factor (publisher) 2025
- 3.6Publisher website ·
- 5-year impact factor (publisher)
- 5.3Publisher website ·
- CiteScore 2026-06
- 5.3LetPub ·
- CiteScore (publisher) 2025
- 1.02Publisher website ·
- SJR 2026-06
- 0.95LetPub ·
- SNIP 2026-06
- 1.02LetPub ·
- h-index
- 47LetPub ·
- h-index
- 126OpenAlex ·
- i10-index
- 2,891OpenAlex ·
- 2-year mean citedness
- 3.16OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 98.91%LetPub ·
Volume
- Articles per year
- 204LetPub ·
- Downloads per year (publisher)
- 577,102Publisher website ·
Articles by year OpenAlex count · 4,729 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 169 | 169 | 60 |
| 2025 | 218 | 218 | 577 |
| 2024 | 228 | 228 | 1,309 |
| 2023 | 249 | 249 | 2,765 |
| 2022 | 271 | 271 | 3,828 |
| 2021 | 351 | 351 | 6,066 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
85 daysMedian, submission to acceptance · P25–P75 71 days – 119 days
- Acceptance to online
- median 16 days (107 articles)
- Submission to online
- median 108 days
- Sample
- 107 articles with submission and acceptance dates (453 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 12%Publisher website ·
- Desk decision
- 44 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,940 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,836 | — | — | |
| LetPub | USD 3,300 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics
- Publication ethics
COPE member Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- NEW ZEALAND
- Language
- English
- ISSN
- 1178-2021
- Print ISSN
- 1176-6328
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Neuropsychiatric Disease and Treatment
What CAS zone is Neuropsychiatric Disease and Treatment in?
In the 2025 upgraded edition of the CAS Journal Ranking, Neuropsychiatric Disease and Treatment is in Zone 3 of Medicine, and in Zone 4 of the minor category Clinical Neurology / Psychiatry. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Neuropsychiatric Disease and Treatment?
The latest impact factor listed by LetPub is 3.22; CiteScore 5.3, h-index 126.
How long does peer review take at Neuropsychiatric Disease and Treatment?
Based on the dates recorded on 107 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 85 days (interquartile range 71–119 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 12%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Neuropsychiatric Disease and Treatment in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Neuropsychiatric Disease and Treatment based?
Of the 31 board members whose country the journal's board page names, 3 (about 10%) are in mainland China; the countries named most often are United States (11), Italy (8) and Japan (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Neuropsychiatric Disease and Treatment?
According to LetPub and DOAJ records, Neuropsychiatric Disease and Treatment is indexed in SCIE, Scopus and DOAJ.
Is Neuropsychiatric Disease and Treatment open access, and what is the APC?
Neuropsychiatric Disease and Treatment is a fully open-access journal. APC about USD 3,940.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .